{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:44:48Z","timestamp":1780098288817,"version":"3.54.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00120-025-02717-z","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T11:09:28Z","timestamp":1762945768000},"page":"1280-1287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Personalisierte Systemtherapie beim Peniskarzinom: Molekulare Zielstrukturen und neue therapeutische Horizonte","Personalized systemic therapy of penile cancer: molecular targets and new therapeutic horizons"],"prefix":"10.1007","volume":"64","author":[{"given":"Gunhild","family":"von Amsberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"2717_CR1","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.eururo.2015.12.007","volume":"69","author":"L Alemany","year":"2016","unstructured":"Alemany\u00a0L, Cubilla\u00a0A, Halec\u00a0G et\u00a0al (2016) Role of human papillomavirus in penile carcinomas worldwide. Eur Urol 69:953\u2013961","journal-title":"Eur Urol"},{"key":"2717_CR2","unstructured":"Anonymous Krebs in Deutschland. In. https:\/\/edoc.rki.de\/handle\/176904\/11438"},{"key":"2717_CR3","unstructured":"Anonymous (2020) S3\u00a0Leitlinie Peniskarzinom. https:\/\/hub.leitlinienprogramm-onkologie.de\/leitlinie\/diagnostik-therapie-und-nachsorge-des-peniskarzinoms"},{"key":"2717_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.2025.43.5_suppl.1","volume":"43","author":"A Bahl","year":"2025","unstructured":"Bahl\u00a0A, Challapalli\u00a0A, Venugopal\u00a0B et\u00a0al (2025) EPIC-A:\u00a0Phase\u00a0II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma. JCO 43:1\u20131","journal-title":"JCO"},{"key":"2717_CR5","unstructured":"(2025) https:\/\/uroweb.org\/guidelines\/penile-cancer"},{"key":"2717_CR6","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/bju.12450","volume":"113","author":"BC Carthon","year":"2014","unstructured":"Carthon\u00a0BC, Ng\u00a0CS, Pettaway\u00a0CA et\u00a0al (2014) Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int 113:871\u2013877","journal-title":"BJU Int"},{"key":"2717_CR7","doi-asserted-by":"crossref","unstructured":"Chadha J, Chahoud J, Spiess PE (2022) An update on treatment of penile cancer. Ther Adv Med Oncol 14: (17588359221127254)","DOI":"10.1177\/17588359221127254"},{"key":"2717_CR8","doi-asserted-by":"crossref","unstructured":"Chadha J, Chahoud J, Spiess PE (2022) An update on treatment of penile cancer. Ther Adv Med Oncol 14: (17588359221127254)","DOI":"10.1177\/17588359221127254"},{"key":"2717_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1200\/JCO.2025.43.5_suppl.9","volume":"43","author":"A Challapalli","year":"2025","unstructured":"Challapalli\u00a0A, Bahl\u00a0A, Venugopal\u00a0B et\u00a0al (2025) EPIC-B:\u00a0Phase\u00a0II trial of cemiplimab as first-line treatment in advanced penile carcinoma. JCO 43:9\u20139","journal-title":"JCO"},{"key":"2717_CR10","doi-asserted-by":"crossref","unstructured":"Cotait Maluf F, Trindade K, Preto D et\u00a0al (2025) Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Advanced Penile Cancer: The Nonrandomized HERCULES (LACOG 0218) Clinical Trial. JAMA Oncol","DOI":"10.1001\/jamaoncol.2025.3266"},{"key":"2717_CR11","doi-asserted-by":"publisher","first-page":"e05443","DOI":"10.1002\/ccr3.5443","volume":"10","author":"S Dai","year":"2022","unstructured":"Dai\u00a0S, Liu\u00a0Y\u2011Y, Liu\u00a0T et\u00a0al (2022) Case report of penile cancer recurrence treated with cetuximab combined with anlotinib. Clin Case Rep 10:e5443","journal-title":"Clin Case Rep"},{"key":"2717_CR12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1517\/14712598.2015.993377","volume":"15","author":"G Di Lorenzo","year":"2015","unstructured":"Di Lorenzo\u00a0G, Buonerba\u00a0C, Ferro\u00a0M et\u00a0al (2015) The epidermal growth factor receptors as biological targets in penile cancer. Expert Opin Biol Ther 15:473\u2013476","journal-title":"Expert Opin Biol Ther"},{"key":"2717_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1479-5876-11-161","volume":"11","author":"G Di Lorenzo","year":"2013","unstructured":"Di Lorenzo\u00a0G, Perdon\u00e0\u00a0S, Buonerba\u00a0C et\u00a0al (2013) Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a\u00a0retropective study. J\u00a0Transl Med 11:161","journal-title":"J Transl Med"},{"key":"2717_CR14","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/jnci\/djad155","volume":"115","author":"T El Zarif","year":"2023","unstructured":"El Zarif\u00a0T, Nassar\u00a0AH, Pond\u00a0GR et\u00a0al (2023) Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. J\u00a0Natl Cancer Inst 115:1605\u20131615","journal-title":"J Natl Cancer Inst"},{"key":"2717_CR15","doi-asserted-by":"crossref","unstructured":"Fahey CC, Nebhan CA, York S et\u00a0al (2023) Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin. Int J Mol Sci 24:","DOI":"10.3390\/ijms242216109"},{"key":"2717_CR16","doi-asserted-by":"publisher","first-page":"e34874","DOI":"10.2196\/34874","volume":"8","author":"L Fu","year":"2022","unstructured":"Fu\u00a0L, Tian\u00a0T, Yao\u00a0K et\u00a0al (2022) Global Pattern and Trends in Penile Cancer Incidence: Population-Based Study. Jmir Public Health Surveill 8:e34874","journal-title":"Jmir Public Health Surveill"},{"key":"2717_CR17","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.euo.2024.04.021","volume":"8","author":"X Garc\u00eda Del Muro","year":"2025","unstructured":"Garc\u00eda Del Muro\u00a0X, P\u00e1ez L\u00f3pez-Bravo\u00a0D, Cu\u00e9llar-Rivas\u00a0MA et\u00a0al (2025) Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase\u00a02 ORPHEUS Study. Eur Urol Oncol 8:278\u2013286","journal-title":"Eur Urol Oncol"},{"key":"2717_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2022.12.008","volume":"49","author":"GD Grass","year":"2023","unstructured":"Grass\u00a0GD, Chahoud\u00a0J, Lopez\u00a0A et\u00a0al (2023) An Analysis of Nectin\u20114 (PVRL4) in Penile Squamous Cell Carcinoma. Eur Urol Open Sci 49:1\u20135","journal-title":"Eur Urol Open Sci"},{"key":"2717_CR19","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/S0022-5347(05)68815-5","volume":"161","author":"GP Haas","year":"1999","unstructured":"Haas\u00a0GP, Blumenstein\u00a0BA, Gagliano\u00a0RG et\u00a0al (1999) Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a\u00a0Southwest Oncology Group study. J\u00a0Urol 161:1823\u20131825","journal-title":"J Urol"},{"key":"2717_CR20","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.3390\/cancers17182956","volume":"17","author":"S Jaime-Casas","year":"2025","unstructured":"Jaime-Casas\u00a0S, Barragan-Carrillo\u00a0R, Eskenazi\u00a0F et\u00a0al (2025) Evaluating the Evolving Treatment Landscape of Systemic Therapies in Penile Cancer. Cancers 17:2956","journal-title":"Cancers"},{"key":"2717_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41585-022-00617-x","volume":"19","author":"VB Joshi","year":"2022","unstructured":"Joshi\u00a0VB, Spiess\u00a0PE, Necchi\u00a0A et\u00a0al (2022) Immune-based therapies in penile cancer. Nat Rev Urol 19:457\u2013474","journal-title":"Nat Rev Urol"},{"key":"2717_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.eururo.2008.04.016","volume":"54","author":"JA Leijte","year":"2008","unstructured":"Leijte\u00a0JA, Kirrander\u00a0P, Antonini\u00a0N et\u00a0al (2008) Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a\u00a0two-centre analysis of 700 patients. Eur Urol 54:161\u2013168","journal-title":"Eur Urol"},{"key":"2717_CR23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden\u00a0MR, Rischin\u00a0D, Schmults\u00a0CD et\u00a0al (2018) PD\u20111 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N\u00a0Engl J Med 379:341\u2013351","journal-title":"N Engl J Med"},{"key":"2717_CR24","doi-asserted-by":"publisher","first-page":"100781","DOI":"10.1016\/j.modpat.2025.100781","volume":"38","author":"JN Mink","year":"2025","unstructured":"Mink\u00a0JN, Eckstein\u00a0M, Khalmurzaev\u00a0O et\u00a0al (2025) Evaluation of Nectin\u20114 and Trop-2: Implications for Patient Outcomes and Therapy in Penile Cancer. Mod Pathol 38:100781","journal-title":"Mod Pathol"},{"key":"2717_CR25","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.clgc.2015.08.001","volume":"14","author":"A Necchi","year":"2016","unstructured":"Necchi\u00a0A, Giannatempo\u00a0P, Vullo\u00a0LS et\u00a0al (2016) Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed. Clin Genitourin Cancer 14:231\u2013236","journal-title":"Clin Genitourin Cancer"},{"key":"2717_CR26","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/bju.14013","volume":"121","author":"A Necchi","year":"2018","unstructured":"Necchi\u00a0A, Vullo\u00a0LS, Perrone\u00a0F et\u00a0al (2018) First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase\u00a02\u00a0study. BJU Int 121:348\u2013356","journal-title":"BJU Int"},{"key":"2717_CR27","doi-asserted-by":"publisher","first-page":"e2348002","DOI":"10.1001\/jamanetworkopen.2023.48002","volume":"6","author":"A Necchi","year":"2023","unstructured":"Necchi\u00a0A, Spiess\u00a0PE, Costa De Padua\u00a0T et\u00a0al (2023) Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden. Jama Netw Open 6:e2348002","journal-title":"Jama Netw Open"},{"key":"2717_CR28","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1038\/bjc.2013.620","volume":"109","author":"S Nicholson","year":"2013","unstructured":"Nicholson\u00a0S, Hall\u00a0E, Harland\u00a0SJ et\u00a0al (2013) Phase\u00a0II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK\/09\/001). Br J Cancer 109:2554\u20132559","journal-title":"Br J Cancer"},{"key":"2717_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41416-021-01574-9","volume":"126","author":"S Nicholson","year":"2022","unstructured":"Nicholson\u00a0S, Tovey\u00a0H, Elliott\u00a0T et\u00a0al (2022) VinCaP: a\u00a0phase\u00a0II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis. Br J Cancer 126:34\u201341","journal-title":"Br J Cancer"},{"key":"2717_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1470-2045(18)30682-X","volume":"20","author":"TB Olesen","year":"2019","unstructured":"Olesen\u00a0TB, Sand\u00a0FL, Rasmussen\u00a0CL et\u00a0al (2019) Prevalence of human papillomavirus DNA and p16(INK4a) in penile cancer and penile intraepithelial neoplasia: a\u00a0systematic review and meta-analysis. Lancet Oncol 20:145\u2013158","journal-title":"Lancet Oncol"},{"key":"2717_CR31","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2010.29.5477","volume":"28","author":"LC Pagliaro","year":"2010","unstructured":"Pagliaro\u00a0LC, Williams\u00a0DL, Daliani\u00a0D et\u00a0al (2010) Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a\u00a0phase\u00a0II study. J\u00a0Clin Oncol 28:3851\u20133857","journal-title":"J Clin Oncol"},{"key":"2717_CR32","doi-asserted-by":"publisher","first-page":"S720","DOI":"10.1016\/j.annonc.2021.08.111","volume":"32","author":"D Pouessel","year":"2021","unstructured":"Pouessel\u00a0D, Beylot-Barry\u00a0M, Esma\u00a0SB et\u00a0al (2021) 715P Nivolumab in pretreated metastatic penile squamous cell carcinoma: Results of the penile cohort from the French AcS&#xe9; prospective program. Ann Oncol 32:S720","journal-title":"Ann Oncol"},{"key":"2717_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.humpath.2016.07.041","volume":"61","author":"SAMTD Amancio","year":"2017","unstructured":"Amancio\u00a0SAMTD, Cunha\u00a0IWD, Neves\u00a0JI et\u00a0al (2017) Epidermal growth factor receptor as an adverse survival predictor in squamous cell carcinoma of the penis. Hum Pathol 61:97\u2013104","journal-title":"Hum Pathol"},{"key":"2717_CR34","doi-asserted-by":"publisher","first-page":"e17517","DOI":"10.1371\/journal.pone.0017517","volume":"6","author":"E Stankiewicz","year":"2011","unstructured":"Stankiewicz\u00a0E, Prowse\u00a0DM, Ng\u00a0M et\u00a0al (2011) Alternative HER\/PTEN\/Akt pathway activation in HPV positive and negative penile carcinomas. Plos One 6:e17517","journal-title":"Plos One"},{"key":"2717_CR35","doi-asserted-by":"publisher","first-page":"113360","DOI":"10.1016\/j.ejca.2023.113360","volume":"194","author":"X Tan","year":"2023","unstructured":"Tan\u00a0X, Wang\u00a0Y, Wu\u00a0Z et\u00a0al (2023) The role of Her\u20112 in penile squamous cell carcinoma progression and cisplatin chemoresistance and potential for antibody-drug conjugate-based therapy. Eur J Cancer 194:113360","journal-title":"Eur J Cancer"},{"key":"2717_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.humpath.2023.10.003","volume":"142","author":"B Tekin","year":"2023","unstructured":"Tekin\u00a0B, Cheville\u00a0JC, Herrera Hernandez\u00a0L et\u00a0al (2023) Assessment of PD-L1, TROP2, and nectin\u20114 expression in penile squamous cell carcinoma. Hum Pathol 142:42\u201350","journal-title":"Hum Pathol"},{"key":"2717_CR37","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/annonc\/mdn149","volume":"19","author":"C Theodore","year":"2008","unstructured":"Theodore\u00a0C, Skoneczna\u00a0I, Bodrogi\u00a0I et\u00a0al (2008) A phase\u00a0II multicentre study of irinotecan (CPT\u00a011) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol 19:1304\u20131307","journal-title":"Ann Oncol"},{"key":"2717_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-021-00246-5","volume":"7","author":"A Thomas","year":"2021","unstructured":"Thomas\u00a0A, Necchi\u00a0A, Muneer\u00a0A et\u00a0al (2021) Penile cancer. Nat Rev Dis Primers 7:11","journal-title":"Nat Rev Dis Primers"},{"key":"2717_CR39","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","volume":"27","author":"AM Udager","year":"2016","unstructured":"Udager\u00a0AM, Liu\u00a0TY, Skala\u00a0SL et\u00a0al (2016) Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Ann Oncol 27:1706\u20131712","journal-title":"Ann Oncol"},{"key":"2717_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12957-024-03305-9","volume":"22","author":"Q Zhang","year":"2024","unstructured":"Zhang\u00a0Q, Li\u00a0Y, Zhang\u00a0Y et\u00a0al (2024) Case report of penile squamous cell carcinoma continuous treatment with BRCA\u00a02 mutation. World J Surg Oncol 22:50","journal-title":"World J Surg Oncol"},{"key":"2717_CR41","doi-asserted-by":"publisher","first-page":"32212","DOI":"10.18632\/oncotarget.4802","volume":"6","author":"S Zhang","year":"2015","unstructured":"Zhang\u00a0S, Zhu\u00a0Y, Ye\u00a0D (2015) Phase\u00a0II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy. Oncotarget 6:32212\u201332219","journal-title":"Oncotarget"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02717-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02717-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02717-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:18:04Z","timestamp":1764598684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02717-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2717"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02717-z","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G. von Amsberg gibt Beratungs- bzw. Gutachtert\u00e4tigkeit in Advisory Boards bei Bayer, Roche, BMS, Astellas, Janssen, MSD, Ipsen, Pfizer, AstraZeneca, Merck, EISAI, Amgen und Novartis an. Honorare\/Vortr\u00e4ge\/Reisekosten\/Kongressunterst\u00fctzung: Bayer, Roche, BMS, Astellas, Ipsen, EISAI, Pierre Fabre, MSD, AstraZeneca, Janssen, Pfizer und Novartis. Finanzierung wissenschaftlicher Untersuchungen: im Rahmen industriegesponserter Studien (Roche, BMS, MSD, AstraZeneca, Sanofi, Pfizer, AvenCell, Lilly, Amgen, Novartis).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}